News articles about Concert Pharmaceuticals (NASDAQ:CNCE) have been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Concert Pharmaceuticals earned a news impact score of 0.21 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 45.6348334253267 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Here are some of the media stories that may have effected Accern Sentiment’s analysis:

Concert Pharmaceuticals (NASDAQ CNCE) traded up $0.36 during trading hours on Tuesday, hitting $20.03. The stock had a trading volume of 125,980 shares, compared to its average volume of 560,627. The company has a market capitalization of $455.68, a P/E ratio of 5.37 and a beta of 1.23. Concert Pharmaceuticals has a fifty-two week low of $8.75 and a fifty-two week high of $30.71.

Concert Pharmaceuticals (NASDAQ:CNCE) last announced its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.16). Concert Pharmaceuticals had a net margin of 62.31% and a negative return on equity of 51.48%. sell-side analysts predict that Concert Pharmaceuticals will post 4.1 earnings per share for the current fiscal year.

A number of analysts recently issued reports on CNCE shares. BidaskClub downgraded Concert Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday, December 22nd. Zacks Investment Research upgraded Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, November 15th. UBS Group set a $34.00 target price on Concert Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, December 19th. Mizuho downgraded Concert Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $23.00 target price for the company. in a research report on Friday, January 12th. Finally, TheStreet upgraded Concert Pharmaceuticals from a “d” rating to a “c+” rating in a research report on Wednesday, November 29th. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $24.33.

In other news, insider Value Fund L. P. Biotechnology sold 1,282,856 shares of the firm’s stock in a transaction on Tuesday, December 19th. The stock was sold at an average price of $26.65, for a total transaction of $34,188,112.40. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Ronald W. Barrett sold 14,156 shares of the firm’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $24.70, for a total value of $349,653.20. Following the transaction, the director now owns 3,539 shares in the company, valued at approximately $87,413.30. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,433,248 shares of company stock worth $37,226,329. Insiders own 10.10% of the company’s stock.

WARNING: This story was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://www.thecerbatgem.com/2018/02/06/concert-pharmaceuticals-cnce-earns-media-impact-rating-of-0-21.html.

Concert Pharmaceuticals Company Profile

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.

Insider Buying and Selling by Quarter for Concert Pharmaceuticals (NASDAQ:CNCE)

Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.